Table 2 Subsequent anti-tumor therapy after study treatment discontinuation
ARX788 (n = 221)* | LC (n = 220)* | |
|---|---|---|
Any | 104 (47.1) | 140 (63.6) |
Radiotherapy | 10 (4.5) | 16 (7.3) |
Operation | 1 (0.5) | 2 (0.9) |
Drug therapy | 99 (44.8) | 131 (59.5) |
Chemotherapy | 89 (40.3) | 95 (43.2) |
Targeted agents | 93 (42.1) | 122 (55.5) |
Anti-HER2 monoclonal antibody | 31 (14.0) | 60 (27.3) |
Anti-HER2 ADC | 3 (1.4) | 44 (20.0) |
Anti-HER2 TKI | 84 (38.0) | 59 (26.8) |
Others | 9 (4.1) | 10 (4.5) |
Anti-CDK4/6 agents | 4 (1.8) | 3 (1.4) |
Anti-VEGF agents | 2 (0.9) | 4 (1.8) |
Anti-mTOR agents | 1 (0.5) | 0 (0.0) |
Anti-PARP agents | 0 (0.0) | 1 (0.5) |
Anti-HER2/CD3 agents | 1 (0.5) | 1 (0.5) |
Anti FR/TRPV6 agents | 1 (0.5) | 1 (0.5) |
Others | 1 (0.5) | 0 (0.0) |
Immunotherapy | 0 (0.0) | 4 (1.8) |
Hormone therapy | 9 (4.1) | 6 (2.7) |
Other systemic therapy | 4 (1.8) | 7 (3.2) |
